Docetaxel-induced photolichenoid eruption

Indian Journal of Pharmacology

Volumn 41, Issue 4, 2009, Pages 203-204

  Vasudevan, Biju ^a   Sawhney, M P S ^a   Sharma, Nitu ^a  

^a BASE HOSPITAL   (India)

Author keywords

Adverse effects; Docetaxel; Lichenoid eruption

Indexed keywords

CORTICOSTEROID; DOCETAXEL; ESTRAMUSTINE PHOSPHATE; PHENIRAMINE AMINOSALICYLATE; SUNSCREEN;

ADULT; ARTICLE; CASE REPORT; DISEASE DURATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOREARM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LICHENOID ERUPTION; LYMPHOCYTIC INFILTRATION; MALE; PROSTATE CANCER; SKIN BIOPSY; SKIN DISCOLORATION;

EID: 70349789994     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.56065     Document Type: Article

References (6)

1. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999;36:99-114.
2. Chiappori A, Devore RF, Johnson DH. New agents in the management of non-small lung cancer. Cancer Control 1997;4:317-325
3. Lyseng-Williamson KA, Fenton C. Docetaxel: A review of its use in metastatic breast cancer. Drugs 2005;65:2513-2531
4. Guitton J, Cohen S, Tranchand B, Vignal B, Droz JP, Guillaumont M, et al. Quantifi cation of docetaxel and its main metabolites in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2005;9:2419-2426
5. Eisenhauer EA, Vermorken JB. The taxoids: Comparative clinical pharmacology and therapeutic potential. Drugs 1998;55:5-30.
6. Aydogan I, Kavak A, Parlak, Alper M, Annakkaya AN, Erbas M. Persistent serpentine supravenous hyperpigmented eruption associated with docetaxel. J Eur Acad Dermatol Venereol 2005;19:345.